Organon News & Analysis

Sun Pharma (SUN) Acquires Organon for $11.75 Billion in Cash

Sun Pharmaceutical Industries (SUN) announced its acquisition of Organon & Co for $11.75 billion, valuing the U.S. firm at $14 per share including debt. This deal will position Sun Pharma among the top 25 global pharmaceutical companies, enhancing its revenue from $12.4 billion. The acquisition is expected to increase Sun Pharma's innovative medicine segment contribution to 27% from 20% in the financial year ending March 2025. Organon's portfolio supports Sun Pharma's strategy to grow its Innovative Medicines business, which includes dermatology and oncology products.